Efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB non-small cell lung cancer (periSCOPE): an open-label, single-arm, phase II trial
The Cancer Research Program of National Cancer Center (NCC201919B02), Shenzhen Clinical Research Center for Cancer (No. [2021]287), Shenzhen High-level Hospital Construction Fund, Shenzhen Key Medical Discipline Construction Fund (SZXK075) and Sanming Project of Medicine in Shenzhen (SZSM201612097) funded this study.
Authors
- Shengcheng Lin (ORCID: https://orcid.org/0000-0002-4919-9300)
- Hongbo Zhao (ORCID: https://orcid.org/0000-0002-7523-9134)
- Songhua Cai (ORCID: https://orcid.org/0000-0003-3839-2030)
- Lixu Wang (ORCID: https://orcid.org/0000-0003-2518-4160)
- Baihua Zhang (ORCID: https://orcid.org/0000-0002-0071-8480)
- Xiangyang Yu (ORCID: https://orcid.org/0000-0002-2372-8905)
- Chujian Huang
- Jie He (ORCID: https://orcid.org/0000-0002-7564-9176)
- Chun-Guang Wang (ORCID: https://orcid.org/0009-0007-4639-7831)
- Xiaotong Guo
- Xin Yu (ORCID: https://orcid.org/0000-0003-3983-4937)
- Chenglin Yang (ORCID: https://orcid.org/0000-0002-0656-9594)
- Yikun Yang (ORCID: https://orcid.org/0009-0005-9074-9510)
- Zhentao Yu
- Longde Du
- Kai Ma (ORCID: https://orcid.org/0000-0001-7535-1313)
- Zhe Wang (ORCID: https://orcid.org/0009-0002-3397-0938)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2024-12-07
- DOI
- https://doi.org/10.1016/j.eclinm.2024.102997
- Citations
- 4
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Innovent Biologics
- Sanming Project of Medicine in Shenzhen